论文部分内容阅读
舒林酸(Sulindac)为吲哚美辛的取代基茚同类物,本品系一种前体药物,在体内吸收后,经生物转化可逆的还原为具有生理活性的含硫代谢物,能有效地抑制前列腺素合成酶,具有抗炎、解热、镇痛作用。已收载于英国药典、欧洲药典、法国药典、荷兰药典、德国药典、瑞士药典。不良反应类型与吲哚美辛相似,发生率从16.9％～15％不等。与其他非甾体抗炎药(NSAID)相比,本品的副作用(特别是胃肠道)较阿司匹林轻,但与布洛芬、炎痛喜康、吲哚美辛相似。现将文献记载舒林酸的不良反应综述如下,以为临床合理用药提供参考。
Sulindac is indomethacin’s substituent of indene analogs, the strain is a prodrug that is absorbed in the body and is reversibly reduced to a physiologically active sulfur-containing metabolite by biotransformation, which is effective Inhibition of prostaglandin synthase, with anti-inflammatory, antipyretic, analgesic effect. Has been included in the British Pharmacopoeia, European Pharmacopoeia, French Pharmacopoeia, Dutch Pharmacopoeia, German Pharmacopoeia, Swiss Pharmacopoeia. Adverse reactions and indomethacin similar types, the incidence rate ranging from 16.9% to 15%. Side effects (especially the gastrointestinal tract) of this product are lighter than aspirin compared to other non-steroidal anti-inflammatory drugs (NSAIDs), but similar to those of ibuprofen, piroxicam and indomethacin. The literature describes the adverse reactions of sulindac summarized below, in order to provide a reference for clinical rational use of drugs.